All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2023-11-24T16:37:33.000Z

What are the current treatment options for intermediate/higher-risk patients with myelofibrosis?

By Oscar Williams
Featured
John Mascarenhas
Nov 24, 2023
Share:
Learning objective: After reading this, learners will be able to cite a new clinical development in myelofibrosis.

Bookmark this article

During the International Academy for Clinical Hematology (IACH) 2023 Congress, the MPN Hub was pleased to speak with John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US. We asked, What are the current treatment options for intermediate/higher-risk patients with myelofibrosis?

Mascarenhas begins by outlining the goals of treatment, focusing on managing anemia in patients with a low platelet count. He then explores the option of bone marrow transplantation and discusses treatment options for patients with a high platelet count. Mascarenhas concludes by delving into emerging treatment options and potential combination therapies.

What are the current treatment options for intermediate/higher risk patients with MF?

More about...
FedratinibIACHMomelotinibMyelofibrosisMyeloproliferative neoplasmsNavitoclaxPacritinibPelabresibPre fibrotic PMFPrimary myelofibrosisRuxolitinib

Related articles

Add bookmark

EHA2023 abstracts: What’s hot in MPN?

To help navigate the exciting content being presented at EHA2023, the MPN Hub Steering Committee have provided their recommendations for the top abstracts to look out for in MPN.

Jun 5, 2023
Add bookmark

EHA2023 abstracts: What’s hot in MPN?

To help navigate the exciting content being presented at EHA2023, the MPN Hub Steering Committee have provided their recommendations for the top abstracts to look...

Jun 5, 2023
Add bookmark

Review of novel agents for myeloproliferative neoplasms

In the last 15 years, there have been rapid advances in understanding the importance and therapeutic potential of the Janus kinase/signal transducers and activators of transcription (JAK/STAT)...

Apr 21, 2020
Add bookmark

Review of novel agents for myeloproliferative neoplasms

In the last 15 years, there have been rapid advances in understanding the importance and therapeutic potential of the Janus kinase/signal...

Apr 21, 2020

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox